Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia.
MPV
TTFT
chronic lymphocytic leukemia
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
01
2020
accepted:
08
09
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
Mean platelet volume (MPV) is a readily accessible and commonly tested hematological indicator. Recent studies revealed a significant impact of MPV on the course and prognosis of many diseases, including some types of cancer, as well as on the incidence of atrial fibrillation and bleeding. The study aimed to perform a retrospective analysis of MPV in terms of time to first treatment (TTFT) and to determine its prognostic value in the group of patients with chronic lymphocytic leukemia (CLL). Moreover, the study includes a retrospective analysis of platelet parameters in patients treated with ibrutinib concerning bleeding and atrial fibrillation. The study included 523 patients with CLL, for 344 the most important cytogenetic aberrations were reported. The Mann-Whitney, Kruskal-Wallis, Kaplan-Meier, chi-squared, log‑rank tests and multivariate Cox proportional hazard regression model were used to analyze collected data. The receiver operating characteristic curve analysis was performed to identify optimal cut-off value for MPV. The analysis of survival curves showed that in the group of patients with higher values of MPV TTFT was significantly longer than in the group with lower MPV (17.9 vs 36 months, p=0.0015, cut-off value for MPV= 10.4 fl). In multivariate Cox proportional hazard regression model low MPV, the presence of del11q and del13q provided independent prognostic value for TTFT (HR=0.69, 95%-CI, 0.5293 to 0.9081; p=0.0078; HR=1.76, 95%-CI, 1.3000 to 2.3882, p=0.0003, HR=0.74, 95%-Cl, 0.5674 to 0.9588, p=0.0229, respectively). In the group treated with ibrutinib, 59 patients had no significant correlation between MPV level and the incidence of therapy complications, although in the group of patients with low MPV there was a tendency for more frequent occurrence of atrial fibrillation (p=0.259). Low MPV values are associated with unfavorable prognosis and might represent a novel, independent prognostic factor in CLL.
Identifiants
pubmed: 33116854
doi: 10.2147/CMAR.S246385
pii: 246385
pmc: PMC7567945
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9977-9985Informations de copyright
© 2020 Masternak et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Sci Rep. 2019 Mar 8;9(1):3959
pubmed: 30850724
Thromb Res. 2016 Mar;139:65-76
pubmed: 26916298
Med Sci Monit Basic Res. 2017 May 12;23:179-222
pubmed: 28496093
Oxid Med Cell Longev. 2014;2014:158135
pubmed: 25383139
Oncol Lett. 2015 Dec;10(6):3419-3424
pubmed: 26788144
Pancreatology. 2019 Mar;19(2):346-351
pubmed: 30638854
Int J Hematol. 2018 Feb;107(2):166-172
pubmed: 29022201
Ann N Y Acad Sci. 1981;370:101-18
pubmed: 6943955
Gut. 2014 Nov;63(11):1721-7
pubmed: 24474383
Platelets. 2014;25(8):592-4
pubmed: 23537073
Br J Haematol. 2017 Jul;178(2):286-291
pubmed: 28397242
Sci Rep. 2017 Jul 27;7(1):6700
pubmed: 28751781
Cancer Metastasis Rev. 2017 Jun;36(2):195-198
pubmed: 28667366
Br J Haematol. 2016 Nov;175(3):462-466
pubmed: 27611233
Leukemia. 2014 Mar;28(3):710-3
pubmed: 24217197
Cancer Biomark. 2018;22(3):559-563
pubmed: 29843218
Nat Rev Dis Primers. 2017 Jan 19;3:16096
pubmed: 28102226
Hematol Oncol. 2018 Feb;36(1):104-109
pubmed: 28736928
Int J Cancer. 2012 Jun 15;130(12):2747-60
pubmed: 22261860
Curr Pharm Des. 2011;17(1):47-58
pubmed: 21247392
Blood. 1975 Aug;46(2):219-34
pubmed: 1139039
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Blood. 2010 Apr 29;115(17):3427-36
pubmed: 20194899
Breast Cancer. 2016 Sep;23(5):752-60
pubmed: 26306738
Clin Chem Lab Med. 2019 Apr 24;57(5):740-744
pubmed: 30307891
Oncotarget. 2017 Jul 12;8(40):68115-68122
pubmed: 28978101
J Urol. 2017 Dec;198(6):1247-1252
pubmed: 28716649
Eur J Haematol. 2017 Oct;99(4):306-314
pubmed: 28646624
Leukemia. 2017 May;31(5):1117-1122
pubmed: 27909342
Kardiol Pol. 2018;76(1):107-118
pubmed: 28980298
Hematol Oncol. 2017 Dec;35(4):456-464
pubmed: 27377517
Lancet Oncol. 2016 Jun;17(6):779-790
pubmed: 27185642
Sci Rep. 2018 Aug 7;8(1):11814
pubmed: 30087357
Asian Pac J Cancer Prev. 2014;15(15):6421-3
pubmed: 25124636
Life Sci. 2016 Mar 1;148:17-23
pubmed: 26872977
J Intern Med. 2008 Dec;264(6):549-62
pubmed: 19017179
Asian Pac J Cancer Prev. 2015;16(7):2671-4
pubmed: 25854344
Redox Biol. 2015 Aug;5:347-357
pubmed: 26122399